BRCA1/2 in Metastatic Prostate Cancer

Video

An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.

Matthew Fowler: What is the role of BRCA1/2 in prostate cancer? What percentage of men with prostate cancer harbor a BRCA1 or BRCA2 mutation?

Alicia Morgans, MD, MPH: BRCA2 is the most common. BRCA1 is much less common. When we think about all the DNA-repair defect alterations that we can target with PARP inhibitors, it’s about 11.8% of men with metastatic cancer. About 10% of these might be BRCA2, and a much smaller percentage might be BRCA1. But BRCA2 is the most common in men with prostate cancer. We’ll often see that these men have an aunt with breast cancer or their mother had ovarian cancer, in addition to male family members who have a history of prostate cancer. As we think about these heritable mutations, it’s important to recognize that they can be associated with not just prostate cancer but cancer syndromes outside prostate cancer, including breast and ovarian cancer.

The other important thing to remember is that the guidelines suggest for germline testing in particular that we don’t do only germline testing in men who are younger at the time of diagnosis or who have family members who have a history of these cancers that may be involved in these syndromes. Because what was so fascinating is that the 11.8% of men with metastatic prostate cancer who have these germline heritable mutations didn’t have a higher rate if they had a family member who had a history of one of these cancers. It can be a clue that we may be ready to see one of these alterations in the germline of one of our patients, but it’s not a clear and definite association that would necessarily guide our germline testing.

This transcript has been edited for clarity.

Related Videos
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Related Content
Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Data Show Short-Course Radiotherapy Increase in Prostate Cancer

November 30th 2023
Article

Realigning value-based models to increase reimbursement for hypofractionated radiotherapy in prostate cancer may minimize barriers to access among underserved communities.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer

November 7th 2023
Article

Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

With the announcement that the supply of 177Lu vipivotide tetraxetan is now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer.

FDA Classifies 177Lu Vipivotide Tetraxetan Drug Shortage as Resolved

October 31st 2023
Article

With the announcement that the supply of 177Lu vipivotidete traxetanis now unconstrained, the targeted radioligand will be available in over 200 centers for patients with prostate cancer. 

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

ONCT-534 Earns FDA Fast Track Designation in R/R Metastatic CRPC

October 27th 2023
Article

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.